Abstract
Expression of BCL-2, BCL-XL, and MCL-1 in acute myelogenous leukemia is highly variable. Cellular BH3 profiling can help decide which are likely to respond to BCL-2-targeted BH3 mimetics.
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / genetics*
-
Peptide Fragments / metabolism*
-
Proto-Oncogene Proteins / metabolism*
-
Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors*
-
Sulfonamides / pharmacology*
Substances
-
Antineoplastic Agents
-
Bax protein (53-86)
-
Bridged Bicyclo Compounds, Heterocyclic
-
Peptide Fragments
-
Proto-Oncogene Proteins
-
Proto-Oncogene Proteins c-bcl-2
-
Sulfonamides
-
venetoclax